REQUEST A DEMO
Total
USD $0.00
Search more companies

Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd. (Malaysia)

Main Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd. Profile Updated: January 24, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2025 Available in: English Download a sample report

Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd. is a company based in Malaysia, with its head office in Kuala Lumpur. It operates in the Drugs and Druggists' Sundries Merchant Wholesalers industry. It was incorporated on July 22, 2004. The latest financial highlights indicate a net sales revenue drop of 4.49% in 2025. Over the same period, its total assets decreased by 14.83%. Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd.’s net profit margin increased by 3.13% in 2025.

Headquarters
D-31-02, Menara Suezcap 1,, No.2 Jalan Kerinchi,
Kuala Lumpur; Federal Territories; Postal Code: 59200

Contact Details: Purchase the Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd. report to view the information.

Basic Information
Registered Capital:
Purchase the Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd. report to view the information.
Financial Auditors:
Purchase the Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd. report to view the information.
Incorporation Date:
July 22, 2004
Key Executives
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Director
Purchase this report to view the information.
Secretary
Purchase this report to view the information.
Secretary
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Glenmark Pharmaceuticals (Malaysia) Sdn. Bhd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency MYR. Absolute financial data is included in the purchased report.
Net sales revenue
-4.49%
Total operating revenue
-4.49%
Operating Profit/Loss (EBIT)
219.27%
EBITDA
165.52%
Net Profit/Loss for the Period
245.72%
Total Assets
-14.83%
Total Equity
18.24%
Operating Profit Margin (ROS)
3.73%
Net Profit Margin
3.13%
Return on Equity (ROE)
10.15%
Quick Ratio
0.21%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?